A Trial Comparing Exposure of Semaglutide When Dosing New Formulations of Oral Semaglutide to Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2018
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 07 Dec 2018 Status changed from active, no longer recruiting to completed.
- 26 Oct 2018 Planned End Date changed from 15 Dec 2018 to 28 Nov 2018.
- 26 Oct 2018 Planned primary completion date changed from 15 Dec 2018 to 28 Nov 2018.